Latest Erythropoietin Stories
NES-ZIONA, Israel, Jan. 18, 2011 /PRNewswire/ -- PROLOR Biotech, Inc., (NYSE Amex: PBTH), today announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd.
Patients with diabetes, kidney disease and anemia who donâ€™t respond to treatment with an anti-anemia drug have a higher risk of cardiovascular disease or death.
HERZLIYA, Israel, December 9, 2010 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd.
BANGALORE, India, December 8, 2010 /PRNewswire/ -- AVESTHAGEN LIMITED, a leading knowledge based life sciences company pioneering the convergence between Food, Pharma and Population Genetics, today announced the completion of manufacturing of the clinical grade material of its first biosimilar molecule- AVDESP(TM) (biosimilar to Darbepoetin alfa), which will now be moving into Clinical Trials.
PALO ALTO, Calif., Dec. 6, 2010 /PRNewswire/ -- Telik, Inc.
THOUSAND OAKS, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it will present data from several key NplateÂ® (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla.
A new drug called FG-2216 can stimulate production of the hormone erythropoietin (EPO) in dialysis patientsâ€”possibly offering a new approach to treatment of kidney disease-related anemia.
The name of the drug is FG-2216, and itâ€™s designed to stimulate production of the hormone erythropoietin (EPO) in dialysis patients.
EXTON, Pa., Nov. 23, 2010 /PRNewswire/ -- BioTrends Research Group, Inc. released ChartTrendsÂ®: Renal Anemia in Chronic Kidney Disease Non-Dialysis (CKD-ND), an annual syndicated publication based on patient and laboratory data collected from over 1,000 US CKD-ND patient charts.
Red-blood-cell-boosting drugs used to treat anemia may undermine breast cancer treatment with Herceptin, a targeted therapy that blocks the cancer-promoting HER2 protein.
- An armed gangster.